For example, inhibitors of DNA methylation showed preclinical efficacy in vitro and in vivo in IDH mutant glioma, and novel second-generation hypomethylating drug guadecitabine with improved pharmacodynamic characteristics is currently tested in a phase III study in AML. The gene discussed is IDH2; the disease is glioma.